University of California San Francisco
Give to UCSF
Natalia Jura Delivers 2022 Byers Award Lecture on Beating Cancer Through Molecular Photography
Natalia Jura, an associate professor in the Department of Cellular and Molecular Pharmacology and an investigator at the UCSF Cardiovascular Research Institute, is the 27th recipient of the annual Byers Award.
UC Regents Approve Plan for New Hospital at Parnassus Heights
UCSF has received approval for plans to build a state-of-the-art hospital at UCSF Helen Diller Medical Center at Parnassus Heights to meet the region’s growing demand for specialty care and California’s rigorous hospital seismic requirements.
Navigating From the Genome to the Clinic Using ‘Cell Maps’
Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute, examines in detail the effects of a handful of genes that seem to play an outsize role in a wide array of diseases.
UCSF Awarded $67.5 Million to Develop New Antiviral Therapies
Scientists at UCSF QBI and the QBI Coronavirus Research Group (QCRG) have been awarded $67.5 million from the National Institute of Allergy and Infectious Diseases (NIAID) to support its mission of pandemic preparedness.
UCSF’s Keith Yamamoto to Lead American Association for the Advancement of Science
Keith Yamamoto, PhD, a leader in precision medicine and the vice chancellor of Science Policy and Strategy at UCSF, has been elected president of the American Association for the Advancement of Science, the largest scientific society in the world.
Bibbins-Domingo, Jones Elected to American Academy of Arts and Sciences
Kirsten B. Bibbins-Domingo and Camara Phyllis Jones join the American Academy of Arts and Sciences’ class of 2022.
Opioid Industry Archive Releases 1.4M Documents from Leading Opioid Maker Implicated in Drug Crisis
UCSF and Johns Hopkins University announced the addition of 1.4 million documents to their Opioid Industry Documents Archive from Mallinckrodt, a leading generic opioid manufacturer now in bankruptcy.
COVID Drug May Also Ease Symptoms of Long COVID
An antiviral drug approved for high-risk COVID patients may also benefit those with long COVID, according to the findings of a small case series that need to be confirmed with future rigorous studies.
